Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

Launched by INSTITUT PASTEUR · Oct 29, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the genetic changes of certain viruses, specifically dengue, Zika, and chikungunya, in New Caledonia from 1995 to 2024. The researchers are particularly interested in how these viruses are affected by a new strategy that involves releasing Aedes aegypti mosquitoes that carry a bacterium called Wolbachia. This bacterium can help reduce the spread of these viruses. By monitoring the evolution of these viruses before and after the release of Wolbachia-carrying mosquitoes, the study aims to understand the impact of this intervention on virus transmission.

To be eligible to participate in the trial, individuals need to show signs of an arbovirus infection within the last week and have a confirmed diagnosis of dengue or another arbovirus through specific testing. Participants will provide a blood sample, which researchers will use to study the virus. This study is important because it helps us learn more about how these viruses evolve and how the Wolbachia strategy might help in controlling their spread. It's essential for potential participants to know that their blood samples will be used for research, but their privacy and rights will be respected throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample,
• • Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus.
• • Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research,
• Exclusion Criteria:
• • Documented opposition from a patient or his representative (s)
• • Previously established viral load too low.
• • Sample obtained from a sample taken more than 7 days after the appearance of clinical signs of infection.